anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
During retrograde autologous priming (RAP), some patients develop hypotension and hemodynamic instability, which impedes the procedure. This study aimed to demonstrate the effects of RAP on transfusion requirements and the development of hemodynamic instability. Overall, 443 patients who were operated upon for coronary artery bypass surgery (CABG) between January 2017 and December 2022 were enrolled and examined, including 162 who underwent RAP (RAP group) and 281 who did not (non-RAP group). Further, data regarding demographic characteristics, preoperative and intraoperative characteristics, and postoperative outcomes of both groups were analyzed. The demographic characteristics and intraoperative data were similar between both groups. Meanwhile, the amount of intraoperative and postoperative blood transfusion and postoperative drainage was lower in the RAP group than in the non-RAP group (P = .001 and .001, respectively). The length of intensive care unit (ICU) stay was shorter in the RAP group, whereas the length of overall hospital stay was the same in both groups. In 17% of the RAP patients, the procedure was terminated following hemodynamic instability. Further, regression analysis revealed body surface area (BSA) and baseline central venous pressure (CVP) as risk factors for the development of hemodynamic instability. In the receiver operating characteristic (ROC) curve analysis, the cutoff values for BSA and CVP were found to be 1.73 (sensitivity = 84.2%, specificity = 80.3%, the area under the ROC curve [AUC] = 0.905) and 4.5 (sensitivity = 97.7%, specificity = 99.7%, AUC = 0.994), respectively. Our finding suggest that RAP is associated with a reduction in the requirement in blood transfusion during both intra-and postoperative periods, as well as a decrease in postoperative drainage. Additionally, the risk of hemodynamic instability during RAP appears to be minimal in patients with a body surface area (BSA) >1.73 and a baseline CVP exceeding 4.5.
Participants will receive handouts with diet and exercise education. Participants will receive a Fitbit to wear continuously 24/7 over 12-weeks to track steps and activity intensity.
Intervention: placebo program: a fixed, primary difficulty level task. 5 x 30 minutes per week, for 7 weeks.
By recognizing that impaired endothelium-dependent arterial vasomotor response, or "endothelial dysfunction", is the central manifestation of both established and pre-clinical atherosclerosis, a nutritional composition has been invented. The composition provides a novel mixture of ingredients each one of which having been chosen on the basis of its demonstrated ability to reverse endothelial dysfunction in individuals suffering from a disease of atherosclerosis or in individuals who are disease-free but carry at least one risk factor for atherosclerosis. The composition consists of pharmacological doses of folic acid, niacin, vitamin C, vitamin E, coenzyme Q, omega-3 polyunsaturated fatty acids, and magnesium salt. It is recognized that any individual who, unpredictably, may be refractory to one or more of the aforementioned agents will likely be responsive to the other agents and thereby receive benefit from the composition as a whole. Furthermore, individuals who are responsive to more than one agent, or all the agents, will enjoy particular benefit from the composition by virtue of the additive effects of the individual agents. Thus, by reversing endothelial dysfunction in at-risk, disease-free individuals, the earliest step of atherogenesis can be blocked and disease development can be prevented; and, by treating individuals afflicted with any one of the diseases of atherosclerosis - coronary artery disease, cerebrovascular disease or peripheral vascular disease - the chance of ischemic attacks can be reduced.
Consenting patients will be approached by a research nurse to complete quality of life questionnaires (baseline measures) either in the oncology clinics or infusion clinics. Patients assigned to early palliative care will meet with a member of the palliative care team after enrollment and completion of the initial questionnaires to receive and review patient-oriented materials detailing palliative care services. Patients will then receive a comprehensive initial consult with a palliative care provider (a trained physician, nurse or nurse practitioner). Additional consults with the palliative care service will be scheduled approximately every 6 weeks for the duration of the study period (one year) at the discretion of the patient and palliative care provider.
Intervention group will be exposed to the use of SaMD CARINAE for 2 months approximately, a patientcentred digital health support program. The intervention trial will include a total of 4 visits: 1. Baseline (2-4 weeks before surgery); 2. Hospital admission (1-3 days before surgery); 3. Hospital discharge (1 week after the surgery approx.); 4. Post-operative day 14 (2 weeks after the surgery approx). After each visit and intervention trial with SaMD CARINAE the experimental group answer the same questionnaires of the control group, above mentioned Participants allocated to the intervention group will also be asked to complete questionnaires about usability, satisfaction and subjective experience.
A composition for improving osteoporosis and increasing bone mineral density, a preparation method of the same and an application of the same in preparation of a health-caring product. The composition comprises an active ingredient and auxiliary materials and is characterized in that the active ingredient includes following components, by weight, 65-85 parts of a raw medicine in an extract of epimedium, 5-15 parts of glucosamine, 5-15 parts of chondroitin sulfate, 1.5-3.5 parts of collagen and a proper amount of vitamin D3; and the auxiliary materials include following components, by weight, 1.5-4.5 parts of an excipient and 0.2-1.5 parts of a lubricant. The composition is designed especially for middle-aged and elderly people and is strong in targeted performance. In the invention, the composition is prepared through integration of Chinese and western medicines, not only is traditional Chinese medicine guide theory inherited but also modern medicinal treatment methods are referenced. An experimental result proves that epimedium in the formula can increases the bone mineral density and the chondroitin sulfate, the glucosamine, the collagen and the vitamin D3 have an effect of improving the osteoporosis. The composition has excellent effects of increasing the bone mineral density and promoting absorption of calcium.
PCT No. PCT/JP96/02187 Sec. 371 Date Feb. 3, 1998 Sec. 102(e) Date Feb. 3, 1998 PCT Filed Aug. 5, 1996 PCT Pub. No. WO97/05882 PCT Pub. Date Feb. 20, 1997An O/W emulsion composition for eye drops comprises a drug selected from the group consisting of fluorometholone, clobetasone butyrate and clobetasol propionate; a phospholipid; liquid paraffine; and water. The O/W emulsion composition is excellent in solubility of fluorometholone, clobetasone butyrate and clobetasol propionate in the tear fluid. Therefore, the composition would exhibit an anti-inflammatory activity identical to or superior to those achieved by the conventional pharmaceutical preparations, by the administration thereof at a dose lower than those for these known drugs. The composition would also be excellent from the economical standpoint and permit reduction of systemic side effects which would be encountered when the conventional drugs are instilled in the eyes.
Morgana is a ubiquitous HSP90 co-chaperone protein coded by the CHORDC1 gene. Morgana heterozygous mice develop with age a myeloid malignancy resembling human atypical myeloid leukemia (aCML), now renamed MDS/MPN with neutrophilia. Patients affected by this pathology exhibit low Morgana levels in the bone marrow (BM), suggesting that Morgana downregulation plays a causative role in the human malignancy. A decrease in Morgana expression levels is also evident in the BM of a subgroup of Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients showing resistance or an incomplete response to imatinib. Despite the relevance of these data, the mechanism through which Morgana expression is downregulated in patients' bone marrow remains unclear. In this study, we investigated the possibility that Morgana expression is regulated by miRNAs and we demonstrated that Morgana is under the control of four miRNAs (miR-15a/b and miR-26a/b) and that miR-15a may account for Morgana downregulation in CML patients.
This will be a prospective crossectional, longitudinal study recruiting patients by invitation with paradoxical low flow low gradient severe aortic stenosis. Patients with PLFLG AS will have been identified in other studies and these patients will be approached for enrollment in the study. Patients deemed appropriate for enrollment will undergo recumbent bicycle stress testing with concomitant measure of gas exchange. The bicycle will be at 30 degrees with initiation of minimal resistance for 3 minutes, followed by an increase in work-rate of 25 watts every two minutes until the patient reaches a sign/symptom-limited maximum exertion or test limiting symptoms develop. Charts will be reviewed for baseline medical conditions and demographics. CPX protocol will be standard HFH protocol supervised by exercise physiologist. The first phase of the study will be investigating if these asymptomatic patients will be reclassified to symptomatic as defined by reduced V02 Max. The second phase will be following these patients for long term adverse events and if V02 max correlates with a higher risk.
Polypeptides comprising all or part of a variant integrin  alpha  subunit A domain or a variant integrin  beta  subunit A-like domain are described. In solution or in membrane-associated form, the A domain or the A-like domain of the polypeptides of the invention exists predominantly in a high affinity conformation. In the polypeptides of the invention, referred to as variant integrin polypeptides, a crucial isoleucine residue (described in greater detail below) is absent. The isoleucine can be either deleted or replaced with different amino acids residue, preferably a smaller or less hydrophobic amino acid residue, e.g., alanine or glycine. Because the variant integrin polypeptides of the invention exist in solution or in membrane-associated form predominantly in a high affinity conformation, they are useful in screening assays for the identification of molecules that bind to (and/or mediate the activity of) an integrin. They are also useful for generating antibodies, e.g., monoclonal antibodies, which bind to the high affinity form of an integrin. Some such antibodies recognize an epitope that is either not present or not accessible on an integrin that is in a lower affinity conformation. The variant integrin polypeptides of the invention can be derived from any integrin  alpha  subunit or any integrin  beta  subunit and could be used therapeutically. The variant integrin polypeptides preferably include a ligand-binding portion of an A-domain or an A-like domain.
Individually titrate meperidine hydrochloride tablets to a dose that provides adequate analgesia and minimizes adverse reactions. If adequate pain management cannot be achieved with a total daily dosage of 600 mg or less, discontinue treatment with meperidine hydrochloride tablets by tapering the dose and select an alternate analgesic.

Continually reevaluate patients receiving meperidine hydrochloride tablets to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.2)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.

If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the meperidine hydrochloride tablets dosage. If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
The study sample consisted of 12 young adult volunteers presenting with TBC of mandible. Local ethical committee approval will be obtained before the trial starts. Laboratory tests (complete blood count, glucose, creatinine, platelets, lipid profile) were performed for all patients. These tests provided an important overview of patient health and a baseline for analysis of the prognosis of PRP use. The process for obtaining PRP basically consists of collection of a 20-mL sample of blood, centrifugation of this sample for 8 min, isolation of a 1-mL aliquot of plasma collected near the erythrocyte fraction. Surgical procedure includes: surgical exploration and injection of PRP to stimulate bone regeneration within the bony cavity . Bone repair was assessed by panoramic X-rays obtained at 2, 4, and 6 months postoperatively. Bone density was measured by area histogram analysis.
The invention provides a method and apparatus for reconstructing magnetic resonance. The device accesses a training set of MRI data for training. The training set may include paired fully sampled data or unpaired fully sampled data. The undersampled MRI data is optimized in an MRI data optimization module to generate reconstructed MRI data. The device uses the training set and reconstructed MRI data to construct a discriminatory model. During the inference, parameters of the identification model are fixed and the identification model is used to classify the output of the MRI data-optimized model as a reconstructed MRI image.
<P>PROBLEM TO BE SOLVED: To provide a PEG (polyethylene glycol)-modified reconstructed Hb (hemoglobin) having an SOD (superoxide dismutase) activity provided with biocompatibility, retentivity in blood and the SOD activity and to provide a method for producing the same.  <P>SOLUTION: The feature is as follows. A metal complex of a cationized porphyrin (or a cationized metal porphyrin complex) is synthesized. Hb is reconstructed by using the synthesized metal complex. The resultant reconstructed hemoglobin is then modified with the polyethylene glycol to carry out the production.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The invention provides a medicament for treating sweaty feet, and belongs to the field of medicines to achieve the aim of healing sweaty feet. According to the technical scheme, the medicament is prepared from the following medicinal materials by weight: 10g of powdered alum, 10g of edible salt and 5g of 45% alcohol. The invention further provides an application of the medicament in treatment of sweaty feet. The medicament is dissolved in boiling water in a proportion being 10g of alum, 10g of edible salt, 5g of alcohol and 1,000g of boiling water. The medicament is used for soaking feet once every night for not less than 30 minutes, one week is taken as a course of treatment, and sweaty feet can be generally cured by three courses of continuous application. According to the medicament provided by the invention, alum and edible salt have the effects of removing toxicity, killing parasite, drying dampness and relieving itching, while alum and alcohol have relatively strong antibacterial property. The medicament is capable of effectively treating sweaty feet.
The present invention discloses a method for using sonication to achieve a homogenized blended oil and trans-resveratrol base and functions as a multi-use men's skin. hair, and anti-aging product for irritated skin. The Trans-resveratrol used in the present disclosure is sourced from Japanese Knotweed,  Polygonum cuspidatum  roots. Trans-resveratrol is a super antioxidant with a high concentration of polyphenols. Trans-resveratrol is derived from the Japanese Knotweed plant and is significantly more potent than the more commonly known, cis-resveratrol. The healing properties of Trans-resveratrol include decreased inflammation, improved cardiovascular health, and anti-aging effects, reduced impact of hangovers and intoxication, increased antioxidants in a person's blood stream, improved the appearance of complexion, reduced impact on skin from exhaustion or lack of sleep, healed body and muscles after exercise, and reduced impact of stress on body.
The present application provides a composition comprising the reaction product of (a) and (b) below: (a) Maleated natural oils, including natural oils having maleated functional groups; and (b) a functionalized or unfunctionalized moiety selected from the group consisting of a hydrophobic moiety, a hydrophilic moiety, and combinations thereof; provided that the hydrophilic moiety is not a glycerol moiety. In another aspect of the application, the application provides a composition comprising the reaction product of (a) - (c) below: (a) Maleated natural oils, including natural oils having maleated functional groups; (b) A functionalized hydrophobic moiety or an unfunctionalized hydrophobic moiety; and (c) a glycerol moiety. In yet another aspect, the present application provides a composition comprising the reaction product of (a) and (b) below: (a) Maleated natural oils, including natural oils having maleated functional groups; (b) Two functionalized hydrophilic moieties or unfunctionalized hydrophilic moieties. The above composition may further comprise a functional system active ingredient. The modified maleated natural oils are useful in a variety of compositions and applications. In yet another aspect of the application, the application provides compounds represented by structure (I).
Subjects in this arm will be asked to alternate between one day of eating as they wish versus one day on a calorie-restricted meal plan. Subjects will follow this alternating meal plan for 3 months.
Patients designated high risk based on protocol will receive 2 cycles of therapy followed by allogeneic transplantation. Patients ≥45 kg (fixed dose): Cycles 1 and 2: 28 mcg daily administered as a continuous infusion on days 1 to 28 of a 6-week treatment cycle.
PURPOSE: To explore the potential causal links between obesity, type 2 diabetes (T2D), and lifestyle choices (such as smoking, alcohol and coffee consumption, and vigorous physical activity) on stress urinary incontinence (SUI), this study employs a Mendelian Randomization approach. This research aims to clarify these associations, which have been suggested but not conclusively established in prior observational studies.
METHODS: Genetic instruments associated with the exposures at the genome-wide significance (p < 5 × 10-8) were selected from corresponding genome-wide association studies. Summary-level data for SUI, was obtained from the UK Biobank. A two-sample MR analysis was employed to estimate causal effects, utilizing the inverse-variance weighted (IVW) method as the primary analytical approach. Complementary sensitivity analyses including MR-PRESSO, MR-Egger, and weighted median methods were performed. The horizontal pleiotropy was detected by using MR-Egger intercept and MR-PRESSO methods, and the heterogeneity was assessed using Cochran's Q statistics.
RESULTS: Our findings demonstrate a significant causal relationship between higher body mass index (BMI) and the risk of SUI, with increased abdominal adiposity (WHRadjBMI) similarly linked to SUI. Smoking initiation is also causally associated with an elevated risk. However, our analysis did not find definitive causal connections for other factors, including T2D, alcohol consumption, coffee intake, and vigorous physical activity.
CONCLUSIONS: These findings provide valuable insights for clinical strategies targeting SUI, suggesting a need for heightened awareness and potential intervention in individuals with higher BMI, WHR, and smoking habits. Further research is warranted to explore the complex interplay between genetic predisposition and lifestyle choices in the pathogenesis of SUI.
The present invention relates to a cryogenic solution for reducing adipose tissue or fat. Delivery of the cryogenic solution to the lipid-rich tissue region induces natural cell death of the adipocytes, thereby depleting the tissue. After cell death, adipocytes are removed by phagocytosis, and local panniculitis or inflammatory reaction of tissues results in further reduction. The low temperature solution is free of ice particles. One or more additives, including salts, sugars, thickeners, freezing point depressants, surfactants, and excipients, may be added to the low temperature solution to promote/enhance fat reduction. The fat reduction by injection of the low temperature solution can be used for improving the appearance of a human or treating body weight related diseases such as obesity.
PURPOSE: Portal hypertension (PHT) and its sequelae are the most clinically important manifestations in cystic fibrosis-related liver disease (CFLD). This paper aimed to evaluate the safety and efficacy of a pre-emptive transjugular intrahepatic portosystemic shunt (TIPS) to prevent PHT-related complications in pediatric patients with CFLD.
METHODS: This was a prospective single-arm study on pediatric patients with CFLD, signs of PHT, and preserved liver function who underwent a pre-emptive TIPS in a single tertiary CF center between 2007 and 2012. The long-term safety and clinical efficacy were assessed.
RESULTS: A pre-emptive TIPS was performed on seven patients with a mean age of 9.2 years (± standard deviation: 2.2). The procedure was technically successful in all patients, with an estimated median primary patency of 10.7 years [interquartile range (IQR) 0.5-10.7)]. No variceal bleeding was observed during the median follow-up of 9 years (IQR 8.1-12.9). In two patients with advanced PHT and rapidly progressive liver disease, severe thrombocytopenia could not be stopped. Subsequent liver transplantation revealed biliary cirrhosis in both patients. In the remaining patients with early PHT and milder porto-sinusoidal vascular disease, symptomatic hypersplenism did not occur, and liver function remained stable until the end of the follow-up. Inclusion for pre-emptive TIPS was discontinued in 2013 following an episode of severe hepatic encephalopathy.
CONCLUSION: TIPS is a feasible treatment with encouraging long-term primary patency to avoid variceal bleeding in selected patients with CF and PHT. However, as the progression of liver fibrosis, thrombocytopenia, and splenomegaly is inevitable, the clinical benefits due to pre-emptive placement appear to be minor.